
Sergio A. Giralt, MD
Hematologic Oncologist
Titles
Deputy Division Head, Division of Hematologic Malignancies; Melvin Berlin Family Chair in Multiple Myeloma; Chief Medical Officer, MSK Direct
Clinical Expertise
Bone Marrow and/or Stem Cell Transplantation for Blood Disorders; Treatment of Multiple Myeloma, Leukemias, and Lymphomas
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Giralt accepts the following list of insurance providers. Select your insurance provider to see more details.
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS, Transplant
Payor Type:
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type:
In Network Coverage Type(s): PPO, HMO
Payor Type:
In Network Coverage Type(s): PPO, HMO, DSN
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type:
In Network Coverage Type(s): HMO
Payor Type:
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO, HMO, PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type:
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO EPO
Payor Type: Commercial
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type:
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO
Payor Type:
In Network Coverage Type(s): Federal Government
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO/OAP
Payor Type: Other
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type:
In Network Coverage Type(s): TBD
Payor Type: Commercial
In Network Coverage Type(s): HMO/EPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, EPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): State Government
Contact and Location
- 646-608-3730 Office Phone
- Speaks English and Spanish

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
See all locationsAbout Me
Education
MD, Universidad Central de Venezuela
Residencies
Internal Medicine - Good Samaritan Hospital
Fellowships
Medical Oncology - MD Anderson Cancer Center
Board Certifications
Internal Medicine; Hematology; Medical Oncology
I am a board-certified hematologist-oncologist, and my clinical activity and research focus on stem cell transplantation for patients with blood disorders. I trained and worked for many years at the University of Texas M.D. Anderson Cancer Center, where I was Deputy Chair of the Department of Stem Cell Transplantation and Cellular Therapies. In May 2010, I joined the faculty of Memorial Sloan Kettering Cancer Center to lead the Adult Bone Marrow Transplant Service and served as Chief until February 2020.
Read more
My research focus has been on improving treatments for older patients who have acute and chronic leukemia. My colleagues and I pioneered the use of reduced-intensity conditioning regimens for older or more debilitated patients with blood cancers. Before this discovery, older patients with these diseases were rarely considered candidates for stem cell transplantation procedures using donor cells because of the toxic effects of high-dose chemotherapy. The development of these less intense and less toxic regimens has allowed us to perform transplants for older patients in a safe and effective manner and has changed the standard of care throughout the world. I plan to continue this research in the context of the pioneering T cell depletion techniques developed at Memorial Sloan Kettering. This new approach has dramatically reduced the risk of graft-versus-host disease, a serious complication of donor stem cell transplantation. Disease recurrence after transplantation remains an important cause of treatment failure, and I am a proponent of post-transplant maintenance therapies using a variety of targeted therapies, which we are continuing to explore at Memorial Sloan Kettering.
I am an expert in the treatment of multiple myeloma, a blood cancer that affects plasma cells (the cells that produce the antibodies that protect us against infections). My research in this area has focused on developing new conditioning regimens for autologous transplant, a treatment approach in which patients receive an infusion of their own stem cells or bone marrow following a course of high-dose chemotherapy, as well as developing strategies that will reduce “symptom burden” and make the treatment so tolerable that it can be done on an outpatient basis. Our goal is to deliver the most effective therapies with minimum symptom burden. I led the Myeloma Intergroup Committee of the Blood and Marrow Clinical Trials Network, which developed the current national study looking at the role of consolidation therapy after autologous stem cell transplant for patients with myeloma.
As a strong believer in collaborative science among large academic centers, I have been involved in many multi-institutional projects and until recently chaired the executive board of the Center for International Blood and Marrow Transplant Research. I am also the past chair of the steering committee of the Blood and Marrow Transplant Clinical Trials Network, a federally funded group that defines the research agenda for stem cell transplantation in the United States.
Awards and Honors
- Castle Connolly: America's Top Doctors (2023)
- Castle Connolly: New York Magazine Top Doctors (2016-2020)
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Giralt
- A Phase II Study of Anti-BCMA CAR T Cell Therapy for Multiple Myeloma After Stem Cell Transplant and Lenalidomide
- Clinical Trials Co-Investigated by Dr. Giralt
- A Phase I Study of Inotuzumab Ozogamicin in People with Acute Lymphocytic Leukemia Who Have Received a Stem Cell Transplant
- A Phase I/II Study of Ipilimumab Immunotherapy after Stem Cell Transplantation in People with Recurrent or Persistent Multiple Myeloma
- A Phase II Study of Iberdomide in People with Multiple Myeloma Who Have Had an Autologous Stem Cell Transplant
Read more
- A Phase III Study of AB-205 or Placebo plus Standard Therapy in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation
- A Pilot Study Assessing the Effects of CAR T-Cell Therapy in Elderly Patients Treated for Lymphoma
- A Pilot Study of Plinabulin and Pegfilgrastim in People with Multiple Myeloma Undergoing an Autologous Stem Cell Transplantation
- A Study Assessing a Mobile App to Help People with Traumatic Stress After a Stem Cell Transplant
- A Study to Assess the Use of Acupuncture to Manage Pain and Other Symptoms Caused by Chemotherapy in People with Multiple Myeloma or Lymphoma
- A Study to See if Anti-BCMA CAR T-Cell Therapy Can Be Made from People with Multiple Myeloma Who Have Had a Stem Cell Transplant
- Pilot Study of Homebound Stem Cell Transplantation for Patients with Multiple Myeloma

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Giralt’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Sergio A. Giralt discloses the following relationships and financial interests:
-
Amgen
Provision of Services -
CSL Behring
Provision of Services -
Caladrius
Provision of Services -
Celgene
Provision of Services -
Ceramedix
Provision of Services -
ExpertConnect
Provision of Services -
GlaxoSmithKline
Provision of Services -
Janssen Research & Development, LLC
Provision of Services -
Karyopharm
Provision of Services
-
Kite Pharmaceuticals
Provision of Services -
Magnolia Innovation
Provision of Services -
Novartis
Provision of Services -
Omeros
Provision of Services -
Pfizer, Inc.
Provision of Services -
Physicians' Education Resource
Provision of Services -
Sanofi US Services Inc.
Provision of Services -
TRM Oncology
Provision of Services -
Xcenda
Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].